精准医疗技术开发商Aitiologic筹集640万欧元种子轮融资，以推进其组织分辨液体活检平台及子痫前期首要项目-动脉网

Aitiologic Raises €6.4 Million in Oversubscribed Seed Financing to Advance Tissue-Resolved Liquid Biopsy Platform and Preeclampsia Lead Program

GlobeNewswire 等信源发布 2026-09-15 09:00



可切换为仅中文







Financing co-led by Heal Capital and Ananda Impact Ventures will advance the Aitios® platform and ongoing validation of lead program to identify preeclampsia risk in a pregnancy’s first trimester

由Heal Capital和Ananda Impact Ventures联合领投的融资将推动Aitios®平台的发展，并持续推进其领先项目的验证工作，以在妊娠早期识别子痫前期风险。

Dr. Gordon Sanghera CBE FRS, co-founder and former CEO of Oxford Nanopore Technologies, joins Aitiologic’s advisory board and participates in the round as an investor

戈登·桑赫拉博士（CBE，FRS），牛津纳米孔技术公司联合创始人兼前首席执行官，加入艾蒂奥逻辑公司顾问委员会，并以投资者身份参与本轮融资

Dr. Rebecca Ertl, obstetrician-gynecologist and founder of a leading prenatal diagnostics center, appointed Chief Medical Officer

丽贝卡·厄特尔博士，一位产科与妇科医生及领先产前诊断中心的创始人，被任命为首席医疗官

VIENNA, September 15, 2026 —

维也纳，2026年9月15日 —

Aitiologic, a precision medicine company developing tissue-resolved liquid biopsy solutions, today announced the close of a significantly oversubscribed €6.4 million (approximately $7.4 million) seed financing, co-led by Heal Capital and Ananda Impact Ventures. The financing will support ongoing large-scale validation and regulated product development of Aitios®, the company’s multi-modal cell-free DNA (cfDNA) platform, initially for first-trimester preeclampsia risk stratification.

Aitiologic是一家致力于开发组织解析液体活检解决方案的精准医疗公司，今日宣布完成一轮大幅超额认购的640万欧元（约合740万美元）种子轮融资，由Heal Capital和Ananda Impact Ventures联合领投。该轮融资将支持公司多模态无细胞DNA（cfDNA）平台Aitios®的大规模验证及合规产品开发工作，该平台最初将用于妊娠早期子痫前期的风险分层。

Dr. Gordon Sanghera CBE FRS, an established pioneer in molecular diagnostics, participated in the seed round as an investor and will join the company’s advisory board. To further advance the clinical translation of the preeclampsia lead program, Dr. Rebecca Ertl has been appointed Chief Medical Officer..

戈登·桑赫拉博士（CBE，FRS）是分子诊断领域的资深先驱，他以投资者身份参与了种子轮融资，并将加入公司顾问委员会。为进一步推动子痫前期主导项目的临床转化，丽贝卡·厄特尔博士已被任命为首席医学官。

Aitios® combines genomic, epigenomic and fragmentomic information from circulating cfDNA with AI-powered interpretation to infer tissue of origin and characterize tissue-specific biological changes from a routine blood draw at single-molecule resolution. The company’s lead program applies the platform to preeclampsia using the same first-trimester blood sample used for non-invasive prenatal testing (NIPT), with the aim of adding information about maternal and placental health without requiring an additional blood draw.

Aitios® 将来自循环游离 DNA（cfDNA）的基因组、表观基因组和片段组信息与人工智能驱动的分析相结合，以单分子分辨率推断组织来源并刻画组织特异性的生物学变化。该公司的核心项目将该平台应用于子痫前期筛查，利用与非侵入性产前检测（NIPT）相同的第一孕期血液样本，旨在无需额外采血的情况下提供有关母体和胎盘健康的信息。

Early identification of women at increased risk for preeclampsia, a major cause of maternal and perinatal morbidity and mortality worldwide, could transform clinical management by guiding preventive treatment and risk-adapted surveillance. Beyond preeclampsia, Aitios® is being developed as a broader tissue-resolved liquid biopsy platform with potential applications in earlier disease detection, patient stratification, therapeutic response assessment and longitudinal disease monitoring..

早期识别子痫前期高风险女性，可透过指导预防性治疗与风险适应性监测，改变临床管理策略；子痫前期是全球孕产妇及围产期发病率和死亡率的主要原因。除子痫前期外，Aitios® 正被开发为一种更广泛的组织解析液体活检平台，其在疾病早期检测、患者分层、治疗反应评估以及疾病纵向监测等方面具有潜在应用价值。

Dr. Andreas E. Posch, CEO and Founder of Aitiologic

Andreas E. Posch 博士，Aitiologic 首席执行官兼创始人

said:

说：

“We have moved from a technology hypothesis to published clinical data and now into an ongoing large-scale validation study of our Aitios® platform in more than 1,000 pregnancies. Preeclampsia is a compelling first application because the unmet need for early risk prediction is significant and the clinical care pathway already exists.

“我们已经从技术假设阶段发展到发布临床数据，并目前进入对我们Aitios®平台在超过1000例妊娠中的持续大规模验证研究。子痫前期是一个引人注目的首个应用方向，因为早期风险预测的未满足需求十分显著，且现有的临床诊疗路径已经建立。”

Longer-term, our ambition is much broader: to transform a routine blood draw into a rich source of molecular information about maternal and fetal health, and ultimately to make tissue-specific biology accessible from blood across a much wider range of conditions. This financing and the addition of Rebecca as CMO and Gordon as an advisor position us to rapidly execute on our robust product development and clinical validation goals to transform physician treatment decisions.”.

从长远来看，我们的雄心更为宏大：将常规的抽血检查转化为关于母婴健康的丰富分子信息源，并最终使通过血液获取组织特异性生物学信息在更广泛的疾病条件下成为可能。此次融资以及丽贝卡担任首席医疗官、戈登担任顾问的加入，使我们能够快速推进强有力的产品研发和临床验证目标，从而变革医生的治疗决策。

Aitios® builds on patented tissue-specific liquid biopsy technology co-invented by Dr. Posch at Siemens Healthineers and exclusively licensed to Aitiologic [1]. The company has since substantially advanced this foundation through proprietary multi-modal cfDNA workflows and AI-driven, tissue-specific interpretation models..

Aitios® 基于由西门子医疗的 Posch 博士共同发明并独家授权给 Aitiologic 的专利组织特异性液体活检技术 [1]。此后，该公司通过专有的多模式 cfDNA 工作流程和人工智能驱动的组织特异性解读模型，大幅推进了这一基础技术的发展。

Seed Funding to Accelerate Advancement of Aitios® Platform

种子资金加速推进Aitios®平台的发展

Heal Capital and Ananda Impact Ventures, two of Europe's leading health-focused venture investors, co-led the financing, with early backers PUSH VC and LANA Ventures continuing their support alongside serial biotech founders with company-building, IPO and exit experience. Proceeds from the financing will support the ongoing development activities for the Aitios® platform, including the large-scale preeclampsia validation study with the Fetal Medicine Foundation.

欧洲两家领先的健康领域风险投资机构 Heal Capital 和 Ananda Impact Ventures 共同领投了本轮融资，早期投资方 PUSH VC 和 LANA Ventures 继续提供支持，同时多位拥有公司构建、首次公开募股（IPO）及退出经验的连续生物科技创业者也参与其中。融资所得将用于支持 Aitios® 平台的持续开发活动，包括与胎儿医学基金会合作开展的大规模子痫前期验证研究。

The study is designed to confirm the findings from Aitiologic's feasibility study and collaboration with Professor Kypros Nicolaides and the Fetal Medicine Research Institute, which demonstrated that tissue-resolved liquid biopsy could stratify risk for both preterm and term preeclampsia from a first-trimester blood draw [2]..

本研究旨在验证Aitiologic的可行性研究结果，以及其与Kypros Nicolaides教授和胎儿医学研究所的合作成果；该合作表明，通过孕早期采血进行的组织解析液体活检能够对早产和足月子痫前期的风险进行分层[2]。

Christian Lautner, Founding Managing Partner, Heal Capital

克里斯蒂安·劳特纳，创始管理合伙人，Heal Capital

stated:

声明：

“Aitiologic is tackling a major unmet need in maternal health with a differentiated approach that fits naturally into an established prenatal workflow. The team has already translated sophisticated liquid biopsy science into published clinical data and is now moving into large-scale validation. That combination of scientific differentiation, clinical relevance and strong execution is exactly what we look for and we are excited to support Aitiologic through its next phase of development.”.

“Aitiologic 正以差异化的方法解决孕产妇健康领域一个重大的未满足需求，该方法能够自然地融入既有的产前诊疗流程。团队已成功将复杂的液体活检技术转化为已发表的临床数据，目前正推进大规模验证工作。这种兼具科学差异性、临床相关性和强大执行力的组合，正是我们所寻求的，我们很高兴能在 Aitiologic 的下一阶段发展中提供支持。”

Dr. Bernd Klosterkemper, Partner, Ananda Impact Ventures

伯恩德·克洛斯特肯珀博士，合伙人，Ananda Impact Ventures

added:

新增：

“We are excited about the opportunity to turn a routine blood draw into a much richer window on human biology. By combining circulating DNA with AI, Aitiologic can reveal where DNA originates and what is happening in the tissue it comes from. Women’s health is a perfect starting point, and preeclampsia is an ideal lead program, where earlier detection and prevention can make a meaningful difference for both mother and child.

“我们对于将常规抽血转化为洞察人类生物学的更丰富窗口这一机遇感到兴奋。通过将循环DNA与人工智能相结合，Aitiologic能够揭示DNA的来源及其源自组织中正在发生的生理变化。女性健康是一个理想的切入点，而子痫前期则是首选的旗舰项目，因为更早的检测和预防能够为母婴健康带来显著改善。”

We believe the same platform has the potential to unlock many additional applications, and are excited to back Andreas and the team.”.

我们相信，该平台有潜力解锁更多应用场景，并对支持安德烈亚斯及其团队感到兴奋。

Addition of Dr. Gordon Sanghera as an Investor and Member of Advisory Board

新增戈登·桑赫拉博士为投资者及 advisory board 成员

As part of the seed financing, Dr. Sanghera, co-founder and former CEO of Oxford Nanopore Technologies, has invested in the round and joins Aitiologic’s advisory board, bringing extensive experience in building, financing and scaling a disruptive multi-modal sequencing technology globally. Dr. Sanghera led Oxford Nanopore Technologies for 21 years, building the company from a spinout of Oxford University to a publicly traded commercial organization on the London Stock Exchange.

作为种子轮融资的一部分，牛津纳米孔技术公司（Oxford Nanopore Technologies）联合创始人兼前首席执行官桑赫拉博士参与了本轮投资，并加入Aitiologic公司的顾问委员会，带来了其在构建、融资以及在全球范围内规模化推广颠覆性多模态测序技术方面的丰富经验。桑赫拉博士领导牛津纳米孔技术公司长达21年，将该公司从牛津大学的一家衍生企业发展成为在伦敦证券交易所上市的商业化组织。

。

Dr. Gordon Sanghera CBE FRS

戈登·桑赫拉博士，大英帝国司令勋章获得者，英国皇家学会院士

commented:

评论：

“Aitiologic is pursuing an extremely attractive opportunity in liquid biopsy: extracting richer, tissue-resolved biological information from circulating cell-free DNA. Andreas and the team have combined strong science with a clear path toward clinical translation, and the early clinical evidence is highly encouraging.

“Aitiologic 正在追求液体活检领域一个极具吸引力的机会：从循环无细胞 DNA 中提取更丰富、具有组织分辨率的生物学信息。Andreas 及其团队将坚实的科学基础与清晰的临床转化路径相结合，早期临床证据令人备受鼓舞。”

I am pleased to invest and look forward to supporting them as they advance the platform and build Aitiologic into a leading precision medicine company.”.

我很高兴进行投资，并期待在他们推进平台发展、将Aitiologic打造成领先的精准医疗公司的过程中提供支持。

Appointment of Dr. Rebecca Ertl as Chief Medical Officer

任命丽贝卡·厄特尔博士为首席医疗官

As Aitiologic advances its product development initiatives and near-term priority in maternal-fetal health, the company also appointed Dr. Rebecca Ertl, an obstetrician-gynecologist and founder of a leading prenatal diagnostics center in Austria, as Chief Medical Officer. In this role, Dr. Ertl will drive the design and execution of Aitiologic's medical strategy for its Aitios® platform, beginning with a preeclampsia program and the eventual expansion within maternal health and other diseases.

随着Aitiologic推进其产品开发计划，并将近期重点放在母婴健康领域，该公司还任命了奥地利领先产前诊断中心的创始人、妇产科医生Rebecca Ertl博士担任首席医疗官。在此职位上，Ertl博士将主导制定并执行Aitiologic旗下Aitios®平台的医疗战略，首先从子痫前期项目入手，随后逐步拓展至更广泛的母婴健康及其他疾病领域。

。

Dr. Rebecca Ertl, CMO of Aitiologic

艾蒂奥逻辑首席医疗官丽贝卡·厄特尔博士

shared:

共享：

“The Aitios® platform offers significant opportunity to better personalize treatment decisions for patients, with immediate impact to address a major pregnancy complication through our preeclampsia program. At the same time, we are beginning to explore whether our single blood draw platform can provide earlier insight into other maternal health conditions that today require separate screening pathways, including gestational diabetes.

“Aitios®平台为更好地个性化患者的治疗决策提供了重大机遇，并通过我们的子痫前期项目对解决一种主要的妊娠并发症产生即时影响。与此同时，我们开始探索我们的单次抽血平台是否能够更早地洞察其他目前需要独立筛查路径的母体健康状况，包括妊娠期糖尿病。”

I am proud to join a team focused on unlocking the broad clinical applications of the Aitios® platform to decode disease and transform patient care.”.

“我自豪地加入一个专注于释放Aitios®平台广泛临床应用的团队，以解码疾病并改变患者护理。”

About Preeclampsia

关于子痫前期

Preeclampsia is a hypertensive disorder affecting an estimated 3 to 8 percent of all pregnancies and a major cause of maternal deaths and fetal deaths worldwide [3,4]. Early identification of women at increased risk for preeclampsia could transform clinical management by guiding preventive treatment and risk-adapted surveillance.

子痫前期是一种高血压性疾病，估计影响所有妊娠的3%至8%，是全球孕产妇死亡和胎儿死亡的主要原因[3,4]。早期识别子痫前期风险增高的女性，可通过指导预防性治疗和基于风险的监测，从而改变临床管理策略。

。

About

关于

Aitiologic

病因学的

Aitiologic is a precision medicine company decoding health by developing tissue-resolved liquid biopsy solutions that enable actionable treatment decisions from a routine blood sample. Its proprietary Aitios® platform combines genomic, epigenomic and fragmentomic signals from circulating cell-free DNA with AI-based interpretation to identify its tissue of origin and characterize underlying biological changes.

Aitiologic 是一家精准医疗公司，通过开发组织解析型液体活检解决方案来解码健康信息，从而基于常规血液样本提供可指导治疗决策的依据。其专有的 Aitios® 平台结合循环无细胞 DNA 的基因组、表观基因组和片段组信号，并利用人工智能进行解读，以识别组织来源并表征潜在的生物学变化。

。

The company’s lead program applies the platform to first-trimester preeclampsia risk assessment, addressing a leading cause of maternal and perinatal morbidity and mortality, with broader applications in precision medicine, patient stratification and disease monitoring.

该公司的旗舰项目将平台应用于妊娠早期子痫前期风险评估，以应对导致孕产妇及围产期发病率和死亡率的主要原因，并在精准医疗、患者分层和疾病监测方面具有更广泛的应用。

Headquartered in Vienna, Aitiologic is supported by non-dilutive grant funding from the Austrian Research Promotion Agency (FFG), Austria Wirtschaftsservice (aws) and the Vienna Business Agency. The company also benefits from support from the European Union through the European Investment Fund (EIF) / InvestEU Fund..

Aitiologic 总部位于维也纳，获得奥地利研究促进署（FFG）、奥地利经济服务公司（aws）和维也纳商务局的非稀释性赠款资助。该公司还受益于欧盟通过欧洲投资基金（EIF）/ InvestEU 基金提供的支持。

Aitios® is currently under development and is not yet approved or available for clinical use.

Aitios® 目前正处于开发阶段，尚未获得批准或用于临床。

Media contact

媒体联系人

Aitiologic

病因学的

Dr. Andreas E. Posch

安德烈亚斯·E·波施博士

Founder & CEO

创始人兼首席执行官

info(at)aitiologic.com